Monday, November 19, 2018
Breakthrough treatment for peanut allergy awaits FDA check
The American College of Allergy, Asthma, and Immunology (ACAAI) recently found that almost 2.5 percent of all children in the United States may live with peanut allergies. For some, even a small trace of peanuts could trigger a life-threatening allergy episode. Those with peanut allergies suffer in their everyday lives because many food products may contain some even the smallest amount of peanuts.
Researchers have done a study on “the effectiveness of a new oral immunotherapy for peanut allergy called AR101, which is ‘a [...] peanut-derived, oral biologic drug that delivers a target daily maintenance dose of 300 milligrams of peanut protein.” The main idea of the treatment is to give peanut exposure to patients with the allergy in order to help build up immunity.
Although this technique has not been accepted by the FDA due to the dangers of performing the experiment, it’s nice to see that researchers are taking into consideration on ways to help people who have peanut allergies. My two best friends have peanut allergies so it would be nice if there was a way to treat these allergies because of their extreme sensitivity to them is concerning.